Article Text

Download PDFPDF
Nanotechnology based therapeutics for lung disease
  1. Mohammad Doroudian1,
  2. Ronan MacLoughlin2,3,4,
  3. Fergus Poynton1,
  4. Adriele Prina-Mello5,6,7,
  5. Seamas C Donnelly1
  1. 1 Department of Medicine, Tallaght University Hospital, Dublin 24 & Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland
  2. 2 Aerogen, IDA Business Park, Galway, Ireland
  3. 3 School of Pharmacy, Royal College of Surgeons, Dublin, Ireland
  4. 4 School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland
  5. 5 CRANN Institute and AMBER Centre, University of Dublin Trinity College, Dublin, Ireland
  6. 6 Department of Medicine, Laboratory for Biological Characterization of Advanced Materials (LBCAM), Trinity College Dublin, Dublin, Ireland
  7. 7 Nanomedicine Group, Trinity Translational Medicine Institute (TTMI), Trinity College Dublin, Dublin, Ireland
  1. Correspondence to Seamas C Donnelly, Department of Medicine, Trinity Centre, Tallaght University Hospital, Dublin 24, Dublin, Ireland; seamas.donnelly{at}tcd.ie

Abstract

Nanomedicine is a multidisciplinary research field with an integration of traditional sciences such as chemistry, physics, biology and materials science. The application of nanomedicine for lung diseases as a relatively new area of interdisciplinary science has grown rapidly over the last 10 years. Promising research outcomes suggest that nanomedicine will revolutionise the practice of medicine, through the development of new approaches in therapeutic agent delivery, vaccine development and nanotechnology-based medical detections. Nano-based approaches in the diagnosis and treatment of lung diseases will, in the not too distant future, change the way we practise medicine. This review will focus on the current trends and developments in the clinical translation of nanomedicine for lung diseases, such as in the areas of lung cancer, cystic fibrosis, asthma, bacterial infections and COPD.

  • lung cancer
  • cystic fibrosis
  • pneumonia
  • asthma
  • copd pharmacology
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors All authors were involved in the writing and sign-off of this review article.

  • Funding SD acknowledges funding from Science Foundation Ireland (SFI) and the Health Research Board (HRB). AP-M acknowledges financial support from Science Foundation Ireland (SFI) under the AMBER Centre Directors Fund project (#12565).

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Airwaves
    The Triumvirate